Hong Kong stock moves | NovaHealth (09969.HK) rose more than 4% in the first half of the year, driven by core products growth, accelerating multiple Phase III clinical trials of in-house drugs.
According to the Securities Times app, Novozymes Health (09969.HK) rose by more than 4%, as of the deadline, it rose by 4.1% to HK$18.01, with a turnover of HK$59.71 million.
Latest
